ASTRO/ESTRO Joint Session – Overview of ASTRO/ESTRO Oligometastatic NSCLC Clinical Practice Guidelines: Case-Based Interactive Discussion

One of the most exciting and rapidly evolving areas of radiation oncology is in its application to the settings of oligometastatic or metastatic disease. Some of the most significant progress has been in implementing local therapy in the management of oligometastatic NSCLC. However, a number of critical questions are unanswered for NSCLC patients and clinical teams, especially in the era of modern systemic therapy (immunotherapies and targeted therapies), including what should define an oligometastatic disease, does local therapy improve overall survival, when should local therapies best be deployed, which local therapies are best, etc. ASTRO/ESTRO developed consensus guidelines to aid patients and medical teams alike to optimize approaches in the local therapy utilization within the context of oligometastatic NSCLC. This education activity explains in detail our guideline recommendations and explores the data surrounding the remaining unanswered questions.

Published in 2023, an evidence-based guidelines for determining how to integrate local therapy in the management of oligometastatic NSCLC was developed by a multi-disciplinary Expert Panel. This effort was jointly developed by the American Society for Radiation Oncology (ASTRO) and European Society for Radiotherapy and Oncology (ESTRO) and was meant to inform multi-disciplinary clinical practice. This Educational activity will 1) address key recommendations from this guideline through case-based interactive discussions; 2) review advanced radiotherapy techniques and technologies, surgical interventions, and systemic therapy roles in managing oligometastatic NSCLC patients; and, 3) highlight the importance of a patient-centered multi-disciplinary decision making process to modern oligometastatic disease management. Subject matter will be presented through individual expert talks and a debate between thought leaders in the field on how to define the OM disease state for NSCLC. 

Topics:

  1. Current Evidence Supportive of Local Therapy in Management of Oligometastatic NSCLC
    Salma Jabbour, MD, FASTRO
  2. Systemic Therapy Considerations when Combined with Local Therapy in Management of OM NSCLC
    Bryan J. Schneider, MD, FASCO
  3. Local Therapy for OM NSCLC: A Surgeon's Perspective
    Mark Berry, MD
  4. The Future of Treating Oligometastatic Disease (OMD) in NSCLC: Dismantling the One-Size-Fits-All Approach
    Jill Feldman, MA
  5. Future Directions: How to Define OMD in NSCLC for Local Therapy
    Suresh Senan, MD, PhD, MBBS
  6. Q and A
    Full Panel

This activity is available from April 9, 2024, through 11:59 p.m. Eastern time on April 8, 2026. 

This activity was originally recorded at the 2023 ASTRO Annual Meeting.

Target Audience

The activity is designed to meet the interests of medical oncologists, radiation oncologists, surgeons, physicists, nurses, diagnostic radiologists, pathologists, radiation therapists, dosimetrists, radiation biologists, pulmonologists, and residents.  

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate into practice key recommendations from the ASTRO/ESTRO jointly-sponsored Guideline on the Use of Local Therapy in the Management of Oligometastatic NSCLC. 
  • Review advanced radiotherapy techniques and technologies, surgical approaches, and systemic therapy utilization for this oligometastatic NSCLC patient population.
  • Implement this knowledge in the development of a patient-centered multidisciplinary decision-making process.  
Course summary
Available credit: 
  • 1.25 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.25 Certificate of Attendance
    This activity was designated for 1.25 AMA PRA Category 1 Credit™.
Course opens: 
04/09/2024
Course expires: 
04/08/2026
Cost:
$0.00
Rating: 
0
  • Puneeth Iyengar, MD, PhD, is employed by University of Texas Southwestern. Dr. Iyengar receives grant research funding from Incyte.
  • Matthias Guckenberger, MD, is employed by University Hospital Zurich. Dr. Guckenberger serves as President elect and Board Member with ESTRO.
  • Salma K. Jabbour, MD, FASTRO, is employed by Rutgers Cancer Institute of New Jersey. Dr. Jabbour receives compensation as a consultant for Merck and Co., Inc., Novocure, Radialogica, IMX Medical, Advarra, and Syntactx. She receives research grant funding from Beigene and Merck and Co., Inc. Dr. Jabbour serves as Deputy Editor for IJROBP.
  • Bryan J. Schneider, MD, FASCO, is employed by University of Michigan. Dr. Schneider serves as a panel member and Vice Chair of the Immunotoxicity Guidelines with the NCCN. 
  • Mark Berry, MD, is employed by Stanford University.
  • Jill Feldman, MA, is employed by EFGR Registers. She receives compensation for her roles as a consultant/advisory board member from EQRx, Janssen, and Blueprint. 
  • Suresh Senan, MD, PhD, MBBS, is employed by Amsterdam University Medical Centers, Cancer Center Amsterdam. Dr. Senan receives grant research funding and/or honoraria from AstraZeneca, Varian Medical Systems, ViewRay Inc., BMS, MSD, and Janssen.   

  

The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity. All relevant relationships have been mitigated.

Disclosure link: 
Committee Disclosures

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.

ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification. 

Available Credit

  • 1.25 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.25 Certificate of Attendance
    This activity was designated for 1.25 AMA PRA Category 1 Credit™.

Price

Cost:
$0.00
Please login or register to take this course.

Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the member rate.

Nonmember: $149
Member: $99
Member-in-training: $49
Student/Grad Student/PGY: $49
Postdoctoral Fellow: $49
 

Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.

Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.

The course and its materials will only be available on the ASTRO website until April 8, 2026, regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.

Required Hardware/software

One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.